Pasar al contenido principal

TRANSLATIONAL RESEARCH IN IMMUNOLOGY AND AGEING: Infectious diseases in the elderly population

RYC2020-028934-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO D'ESTUDIS SUPERIORS EN CIENCIES DE LA SALUT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunoaging at Early Ages Could Drive a Higher Comorbidity Burden in People with HIV on Antiretroviral Therapy Compared with the Uninfected Population

  • Loste, Cora
  • Trigueros Peña, Macedonia|||0000-0003-4156-1018
  • Muñoz-López, Francisco|||0000-0003-1789-1658
  • Urrea, Víctor|||0000-0002-2577-856X
  • Martínez, Ana
  • González, Sandra
  • Puig, Jordi|||0000-0002-4075-0346
  • Martín Flix, Marta|||0000-0001-7849-3616
  • Bonjoch, Anna|||0000-0002-5343-2881
  • Echeverría, Patricia|||0000-0003-2755-3695
  • Massanella, Marta|||0000-0002-3326-151X
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
This is an observational, cross-sectional, comparative case-control, pilot study aimed at assessing the impact of HIV infection and age on immunological markers in people with HIV (PWH) on antiretroviral therapy (ART). The study included 40 PWH on ART, divided into two age groups (40-45 years vs. ≥60 years), and 30 HIV-uninfected controls matched by sex and age. The results show that older PWH on ART had more comorbidities and a higher frequency of CD8 T cells compared to older controls, with a significant decrease in CD8 naïve T cells with age. Additionally, younger PWH on ART exhibited higher frequencies of activated CD8 T cells and elevated levels of inflammatory markers (sCD14, IL-6) compared to age-matched controls, with values similar to those of older PWH on ART. These findings suggest that younger PWH on ART may experience accelerated immunoaging, highlighting the need for early interventions in this population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma exchange therapy for the post COVID-19 condition, a phase II, double-blind, placebo-controlled, randomized trial

  • España Cueto, Sergio|||0000-0002-3026-132X
  • Loste, Cora
  • Lladós, Gemma
  • López, Cristina
  • Santos, José Ramón|||0000-0002-0886-7114
  • Dulsat, Gemma
  • García, Anna
  • Carmezim, João
  • Carabia, Júlia
  • Ancochea, Águeda
  • Fernández-Prendres, Carla
  • Morales-Indiano, Cristian|||0000-0003-0497-6003
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Sanchez, Anna
  • Parraga, Ivonne Graciela
  • Chamorro, Anna
  • San José, Alba
  • Abad, Elena|||0000-0001-5172-4162
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Prats, Anna|||0000-0002-3586-4525
  • Fumaz, Carmina R.|||0000-0003-0838-3395
  • Coll-Fernandez, Roser|||0000-0003-4943-2376
  • Estany Quera, Carla|||0000-0001-6993-5865
  • Torrano, Pamela
  • Puig, Jordi|||0000-0002-4075-0346
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Tebé, Cristian|||0000-0003-2320-1385
  • Massanella, Marta|||0000-0002-3326-151X
  • Paredes, Roger|||0000-0002-6553-691X
  • Mateu, Lourdes|||0000-0001-7223-7611
The post-COVID-19 condition (PCC) is a highly debilitating and persistent postinfectious syndrome that affects millions of people worldwide and has no effective treatment. Therapeutic plasma exchange (TPE) has the potential to improve the PCC by clearing the peripheral soluble pro-inflammatory immune milieu derived from acute or persistent SARS-CoV-2 infection. In a phase II, double-blind, placebo-controlled, randomized trial, fifty subjects with PCC were randomly assigned (1:1) to receive six sessions of either TPE or a sham plasma exchange and were followed for 90 days (ClinicalTrials.gov registration: NCT05445674). The primary endpoint was safety; secondary endpoints included functional status, symptomology, quality of life, neurocognitive symptoms, and peripheral biochemistry, hematology, coagulation and inflammation parameters. Both study arms had a similarly favorable safety profile. There were no diferences between groups in any of the efficacy parameters evaluated. Whereas TPE is safe, it did not lead to any discernible improvement of the PCC in this clinical trial.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters

  • Pedreño López, Núria|||0000-0001-6927-2301
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Usai, Carla|||0000-0002-6373-2765
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Benet, Susana|||0000-0002-2219-8826
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Avila-Nieto, Carlos
  • Roca, Núria
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pérez, Mònica
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Matilla, Marina
  • Revollo, Boris|||0000-0001-9245-2183
  • Hernández, Agnes
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Moltó, Jose
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Massanella, Marta|||0000-0002-3326-151X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Carrillo, Jorge|||0000-0003-0221-5948
Severe COVID-19 associates with humoral immune response dysregulation. While antibodies confer protection against SARS-CoV-2, evidence also support their putative contribution to disease severity. Our study demonstrates that higher levels of S2-IgG, and S2-, RBD-, and Nucleocapsid-IgA differentiate severe and non-severe cases. However, no major antibody functional differences are found between both COVID-19 manifestations. Enhanced Fc-dependent functions in severe cases are primarily driven by increased antibody titers. No differences in antibody avidity are found between severe and non-severe cases, but a gradation in binding strength across specificities suggests that early anti-RBD, -S2, and -Nucleocapsid antibodies may originate from different pathways. In golden Syrian hamsters, S2 immunization or transfer of RBD-depleted antibodies isolated from severe and non-severe cases promote a faster clinical recovery after SARS-CoV-2 challenge, despite a transient initial weight loss. These findings indicate that antibodies are not major determinants of COVID-19 severity and suggest additional factors influencing disease outcomes. Functional analysis of antibody responses against SARS-CoV-2 shows their role in the development of SARS-CoV-2-induced severe disease in golden Syrian hamsters.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study

  • Abella Monreal, Eugenia
  • García-Pallarols, Francesc
  • Lahsen, Randa Ben Azaiz Ben
  • CoronAVI@S studies
SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients., This work was partially funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant DSL0016 to J Blanco and Grant DSL015 to J Carrillo), the Spanish Health Institute Carlos III (Grant PI17/01518 and PI20/00093 to J Blanco and PI18/01332 to J Carrillo), Fundació Gloria Soler, and the crowdfunding initiatives https://www.yomecorono.com, BonPreu/Esclat and Correos. M Trigueros was supported by a doctoral fellowship from the Departament de Salut from Generalitat de Catalunya (SLT017/20/000095). F Muñoz-Lopez is supported by a doctoral grant from Sorigué Foundation. E Pradenas was supported by a doctoral grant from ANID, Chile: Grant 72180406. M Massanella was granted with RYC2020-028934-I/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and State Research Agency, MCIN/AEI/10.13039/501100011033 and the European Social Fund “investing in your future.”
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters

  • Pedreño-López, Núria
  • Tarrés Freixas, Ferran
  • Usai, Carla
  • Raïch-Regué, Dalia
  • Benet, Susana
  • Ainsua-Enrich, Erola
  • Carabelli, Julieta
  • Pradenas, Edwards
  • Ávila-Nieto, Carlos
  • Roca, Núria
  • Cantero, Guillermo
  • Pérez, Mònica
  • de la Concepción, Maria Luisa Rodríguez
  • Matilla, Marina
  • Revollo, Boris
  • Hernández, Agnes
  • Abad-Capa, Jorge
  • Mothe, Beatriz
  • Moltó, Jose
  • Mateu, Lourdes
  • Massanella, Marta
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Carrillo, Jorge
Severe COVID-19 associates with humoral immune response dysregulation. While antibodies confer protection against SARS-CoV-2, evidence also support their putative contribution to disease severity. Our study demonstrates that higher levels of S2-IgG, and S2-, RBD-, and Nucleocapsid-IgA differentiate severe and non-severe cases. However, no major antibody functional differences are found between both COVID-19 manifestations. Enhanced Fc-dependent functions in severe cases are primarily driven by increased antibody titers. No differences in antibody avidity are found between severe and non-severe cases, but a gradation in binding strength across specificities suggests that early anti-RBD, -S2, and -Nucleocapsid antibodies may originate from different pathways. In golden Syrian hamsters, S2 immunization or transfer of RBD-depleted antibodies isolated from severe and non-severe cases promote a faster clinical recovery after SARS-CoV-2 challenge, despite a transient initial weight loss. These findings indicate that antibodies are not major determinants of COVID-19 severity and suggest additional factors influencing disease outcomes., The authors would like to thank all the patients who participated in this study, the scientific and technical services at IrsiCaixa, and the people who are supporting our research through the MaratoTV3 (618/C/2021), CERCA Programme/Generalitat de Catalunya, Direcció General de Recerca i Innovació en Salut (SLD0015 and SLD0016), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, CIBERINFEC, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU, and the following crowdfunding projects: “YomeCorono”, BonPreu/Esclat, and Correos. In addition, this research was supported partially by the AGAUR (Generalitat de Catalunya), 2021 SGR 00452 (GRC. GRUP DE RECERCA BÀSICA I CLINICA A LES MALALTIES INFECCIOSES. CAN and EP were supported by Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742) and National Agency for Research and Development of Chile (ANID: 72180406), respectively. NPL was funded by Juan de la Cierva postdoctoral fellowship (FJC2021-047205-I). MM was granted with RYC2020-028934-I/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and State Research Agency and the European Social Fund “investing in your future”. Drawing in Figs. 5 and 7 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study

  • Abella Monreal, Eugenia
  • García-Pallarols, Francesc
  • Lahsen, Randa Ben Azaiz Ben
  • CoronAVI@S studies
SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients., This work was partially funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant DSL0016 to J Blanco and Grant DSL015 to J Carrillo), the Spanish Health Institute Carlos III (Grant PI17/01518 and PI20/00093 to J Blanco and PI18/01332 to J Carrillo), Fundació Gloria Soler, and the crowdfunding initiatives https://www.yomecorono.com, BonPreu/Esclat and Correos. M Trigueros was supported by a doctoral fellowship from the Departament de Salut from Generalitat de Catalunya (SLT017/20/000095). F Muñoz-Lopez is supported by a doctoral grant from Sorigué Foundation. E Pradenas was supported by a doctoral grant from ANID, Chile: Grant 72180406. M Massanella was granted with RYC2020-028934-I/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and State Research Agency, MCIN/AEI/10.13039/501100011033 and the European Social Fund “investing in your future.”
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters

  • Pedreño-López, Núria
  • Tarrés Freixas, Ferran
  • Usai, Carla
  • Raïch-Regué, Dalia
  • Benet, Susana
  • Ainsua-Enrich, Erola
  • Carabelli, Julieta
  • Pradenas, Edwards
  • Ávila-Nieto, Carlos
  • Roca, Núria
  • Cantero, Guillermo
  • Pérez, Mònica
  • de la Concepción, Maria Luisa Rodríguez
  • Matilla, Marina
  • Revollo, Boris
  • Hernández, Agnes
  • Abad-Capa, Jorge
  • Mothe, Beatriz
  • Moltó, Jose
  • Mateu, Lourdes
  • Massanella, Marta
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Carrillo, Jorge
Severe COVID-19 associates with humoral immune response dysregulation. While antibodies confer protection against SARS-CoV-2, evidence also support their putative contribution to disease severity. Our study demonstrates that higher levels of S2-IgG, and S2-, RBD-, and Nucleocapsid-IgA differentiate severe and non-severe cases. However, no major antibody functional differences are found between both COVID-19 manifestations. Enhanced Fc-dependent functions in severe cases are primarily driven by increased antibody titers. No differences in antibody avidity are found between severe and non-severe cases, but a gradation in binding strength across specificities suggests that early anti-RBD, -S2, and -Nucleocapsid antibodies may originate from different pathways. In golden Syrian hamsters, S2 immunization or transfer of RBD-depleted antibodies isolated from severe and non-severe cases promote a faster clinical recovery after SARS-CoV-2 challenge, despite a transient initial weight loss. These findings indicate that antibodies are not major determinants of COVID-19 severity and suggest additional factors influencing disease outcomes., The authors would like to thank all the patients who participated in this study, the scientific and technical services at IrsiCaixa, and the people who are supporting our research through the MaratoTV3 (618/C/2021), CERCA Programme/Generalitat de Catalunya, Direcció General de Recerca i Innovació en Salut (SLD0015 and SLD0016), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, CIBERINFEC, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU, and the following crowdfunding projects: “YomeCorono”, BonPreu/Esclat, and Correos. In addition, this research was supported partially by the AGAUR (Generalitat de Catalunya), 2021 SGR 00452 (GRC. GRUP DE RECERCA BÀSICA I CLINICA A LES MALALTIES INFECCIOSES. CAN and EP were supported by Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742) and National Agency for Research and Development of Chile (ANID: 72180406), respectively. NPL was funded by Juan de la Cierva postdoctoral fellowship (FJC2021-047205-I). MM was granted with RYC2020-028934-I/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and State Research Agency and the European Social Fund “investing in your future”. Drawing in Figs. 5 and 7 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Calba, Ignasi
  • Massanella, Marta|||0000-0002-3326-151X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Badia, Roger|||0000-0003-3982-7577
HIV latent infection may be associated with disrupted viral RNA sensing, interferon (IFN) signaling, and/or IFN stimulating genes (ISG) activation. Here, we evaluated the use of compounds selectively targeting at the inhibitor of nuclear factor-κB (IκB) kinase (IKK) complex subunits and related kinases (TBK1) as a novel pathway to reverse HIV-1 latency in latently infected non-clonal lymphoid and myeloid cell in vitro models. IKK inhibitors (IKKis) triggered up to a 1.8-fold increase in HIV reactivation in both, myeloid and lymphoid cell models. The best-in-class IKKis, targeting TBK-1 (MRT67307) and IKKβ (TCPA-1) respectively, were also able to significantly induce viral reactivation in CD4+ T cells from people living with HIV (PLWH) ex vivo. More importantly, although none of the compounds tested showed antiviral activity, the combination of the distinct IKKis with ART did not affect the latency reactivation nor blockade of HIV infection by ART. Finally, as expected, IKKis did not upregulate cell activation markers in primary lymphocytes and innate immune signaling was blocked, resulting in downregulation of inflammatory cytokines. Overall, our results support a dual role of IKKis as immune modulators being able to tackle the HIV latent reservoir in lymphoid and myeloid cellular models and putatively control the hyperinflammatory responses in chronic HIV-1 infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Determinants of the onset and prognosis of the post-COVID-19 condition, a 2-year prospective observational cohort study

  • Mateu, Lourdes|||0000-0001-7223-7611
  • Tebé, Cristian|||0000-0003-2320-1385
  • Loste, Cora
  • Santos, José Ramón|||0000-0002-0886-7114
  • Lladós, Gemma
  • López, Cristina
  • España Cueto, Sergio|||0000-0002-3026-132X
  • Toledo, Ruth
  • Font, Marta
  • Chamorro, Anna
  • Muñoz-López, Francisco|||0000-0003-1789-1658
  • Nevot Banús, Maria|||0000-0003-4947-4648
  • Vallejo, Nuria
  • Teis, Albert|||0000-0002-4820-0736
  • Puig, Jordi|||0000-0002-4075-0346
  • Fumaz, Carmina R.|||0000-0003-0838-3395
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Prats, Anna|||0000-0002-3586-4525
  • Estany Quera, Carla|||0000-0001-6993-5865
  • Coll-Fernandez, Roser|||0000-0003-4943-2376
  • Herrero, Cristina
  • Casares, Patricia
  • Garcia, Ana
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Paredes, Roger|||0000-0002-6553-691X
  • Massanella, Marta|||0000-0002-3326-151X
At least 5-10% of subjects surviving COVID-19 develop the post-COVID-19 condition (PCC) or "Long COVID". The clinical presentation of PCC is heterogeneous, its pathogenesis is being deciphered, and objective, validated biomarkers are lacking. It is unknown if PCC is a single entity or a heterogeneous syndrome with overlapping pathophysiological basis. The large US RECOVER study identified four clusters of subjects with PCC according to their presenting symptoms. However, the long-term clinical implications of PCC remain unknown. We conducted a 2-year prospective cohort study of subjects surviving COVID-19, including individuals fulfilling the WHO PCC definition and subjects with full clinical recovery. We systematically collected post-COVID-19 symptoms using prespecified questionnaires and performed additional diagnostic imaging tests when needed. Factors associated with PCC were identified and modelled using logistic regression. Unsupervised clustering analysis was used to group subjects with PCC according to their presenting symptoms. Factors associated with PCC recovery were modelled using a direct acyclic graph approach. The study included 548 individuals, 341 with PCC, followed for a median of 23 months (IQR 16.5-23.5), and 207 subjects fully recovered. In the model with the best fit, subjects who were male and had tertiary studies were less likely to develop PCC, whereas a history of headache, or presence of tachycardia, fatigue, neurocognitive and neurosensitive complaints and dyspnea at COVID-19 diagnosis predicted the development of PCC. The cluster analysis revealed the presence of three symptom clusters with an additive number of symptoms. Only 26 subjects (7.6%) recovered from PCC during follow-up; almost all of them (n = 24) belonged to the less symptomatic cluster A, dominated mainly by fatigue. Recovery from PCC was more likely in subjects who were male, required ICU admission, or had cardiovascular comorbidities, hyporexia and/or smell/taste alterations during acute COVID-19. Subjects presenting with muscle pain, impaired attention, dyspnea, or tachycardia, conversely, were less likely to recover from PCC. Preexisting medical and socioeconomic factors, as well as acute COVID-19 symptoms, are associated with the development of and recovery from the PCC. Recovery is extremely rare during the first 2 years, posing a major challenge to healthcare systems.